The state of Texas currently has 239 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
NCT06016270
Recruiting
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881
Recruiting
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mort... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/15/2024
Locations: Elligo Health Research, Inc., Austin, Texas
Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Register for Updates
Lung EpiCheck Biomarkers Development Study
NCT06245876
Recruiting
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
02/08/2024
Locations: Urology San Antonio, San Antonio, Texas
Conditions: Lung Cancer
Register for Updates
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
NCT05563272
Recruiting
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
01/24/2024
Locations: Austin Radiological Association (ARA), Austin, Texas
Conditions: Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
Register for Updates
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
NCT05987189
Recruiting
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
01/12/2024
Locations: Baptist Hospitals of Southeast Texas, Beaumont, Texas
Conditions: Lung Cancer
Register for Updates
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
NCT05094804
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: NEXT Austin, Austin, Texas +1 locations
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Register for Updates
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT04075305
Recruiting
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: Md Anderson Cancer Center, Houston, Texas
Conditions: Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
Register for Updates
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Texas Oncology - Tyler, Tyler, Texas
Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Register for Updates
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247
Recruiting
This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: Michael E. Debakey VA Medical Center, Houston, Texas +1 locations
Conditions: Stage IV Non-small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma, Stage IV Malignant Melanoma
Register for Updates
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
NCT05736029
Recruiting
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: Baylor Scott and White Research Institute, Dallas, Texas
Conditions: Non Small Cell Lung Cancer, Healthy
Register for Updates
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472
Recruiting
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
Register for Updates